| Not Yet Recruiting | A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems NCT07486102 | Boehringer Ingelheim | Phase 1 |
| Not Yet Recruiting | MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function NCT03606538 | Lykos Therapeutics | Phase 1 |
| Recruiting | Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Part NCT07457229 | GRIN Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Live NCT07269301 | Pfizer | Phase 1 |
| Not Yet Recruiting | A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Pa NCT07248839 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) NCT07219550 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015) NCT07025551 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls NCT07018492 | Shionogi | Phase 1 |
| Recruiting | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavol NCT07144111 | Genentech, Inc. | Phase 1 |
| Recruiting | A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems NCT07023354 | Boehringer Ingelheim | Phase 1 |
| Completed | Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With NCT06736223 | Italfarmaco | Phase 1 |
| Recruiting | Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) NCT06962332 | Exelixis | Phase 1 |
| Completed | A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009) NCT06860243 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib NCT06997276 | SpringWorks Therapeutics, Inc. | Phase 1 |
| Recruiting | An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Mod NCT06952634 | Alumis Inc | Phase 1 |
| Recruiting | Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal NCT06911320 | Atea Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement NCT06985615 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy A NCT06908954 | Ipsen | Phase 1 |
| Completed | A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Funct NCT07428525 | Amgen | Phase 1 |
| Withdrawn | Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Match NCT05490030 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of A NCT06812780 | AstraZeneca | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired H NCT06734208 | Genentech, Inc. | Phase 1 |
| Completed | Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD NCT06813781 | AstraZeneca | Phase 1 |
| Completed | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001 NCT06619054 | Kaken Pharmaceutical | Phase 1 |
| Completed | Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant NCT06928779 | Corcept Therapeutics | Phase 1 |
| Recruiting | Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment NCT06740799 | Daiichi Sankyo | Phase 1 |
| Completed | A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030) NCT06575959 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | A Study of RAY1225 in Participants With Impaired Liver Function NCT06577415 | Guangdong Raynovent Biotech Co., Ltd | Phase 1 |
| Completed | Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants Wi NCT06535399 | Celgene | Phase 1 |
| Completed | Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD NCT06576765 | AstraZeneca | Phase 1 |
| Completed | Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different D NCT06425198 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Partici NCT06402721 | Bayer | Phase 1 |
| Completed | Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Bal NCT06388616 | AstraZeneca | Phase 1 |
| Completed | A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and NCT06352528 | Bristol-Myers Squibb | Phase 1 |
| Completed | Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment NCT06671509 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Unknown | Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome NCT06179368 | Assiut University | — |
| Completed | PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic F NCT06048302 | NewAmsterdam Pharma | Phase 1 |
| Completed | A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) NCT06052566 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | DZD9008 PK Study in Hepatic Impairment Subjects NCT06084104 | Dizal Pharmaceuticals | Phase 1 |
| Completed | A Study About Fazirsiran in People With and Without Liver Problems NCT05891158 | Takeda | Phase 1 |
| Completed | A Study of TAK-279 in Adults With or Without Liver Damage NCT05976321 | Takeda | Phase 1 |
| Completed | Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment NCT06161259 | Guangdong Raynovent Biotech Co., Ltd | Phase 1 |
| Completed | A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With NCT05917938 | Novo Nordisk A/S | Phase 1 |
| Completed | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine NCT05935033 | AbbVie | Phase 1 |
| Completed | A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693 NCT05919069 | AstraZeneca | Phase 1 |
| Completed | Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment NCT05856513 | Guangdong Raynovent Biotech Co., Ltd | Phase 1 |
| Completed | A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of NCT05857644 | Pfizer | Phase 1 |
| Completed | A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic I NCT05835180 | Sagimet Biosciences Inc. | Phase 1 |
| Completed | GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers NCT05814926 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 1 |
| Completed | A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced NCT05564104 | Novo Nordisk A/S | Phase 1 |
| Completed | Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment NCT05751759 | AstraZeneca | Phase 1 |
| Unknown | Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject NCT05684653 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 |
| Completed | Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function NCT05765344 | Gilead Sciences | Phase 1 |
| Completed | A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With NCT05674474 | Institut de Recherches Internationales Servier | Phase 1 |
| Completed | A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Functi NCT06126575 | Stemline Therapeutics, Inc. | Phase 1 |
| Unknown | Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir NCT05731804 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female NCT05790304 | AstraZeneca | Phase 1 |
| Completed | A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment NCT05707390 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects NCT05706623 | VectivBio AG | Phase 1 |
| Completed | Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function NCT05724693 | Atea Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study to Evaluate the Safety, Tolerability, and PK of Pacritinib NCT05552183 | CTI BioPharma | Phase 1 |
| Completed | Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function NCT05515445 | Chipscreen Biosciences, Ltd. | Phase 1 |
| Completed | Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepati NCT05599932 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Particip NCT06736340 | Noucor Health S.A. | Phase 1 |
| Completed | A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment NCT05753592 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic F NCT05582187 | Basilea Pharmaceutica | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With NCT05517525 | Insmed Incorporated | Phase 1 |
| Recruiting | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 NCT05484206 | Vir Biotechnology, Inc. | Phase 1 |
| Completed | A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Parti NCT05409911 | Shionogi | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Vario NCT05481411 | Amgen | Phase 1 |
| Terminated | Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment NCT05517226 | AstraZeneca | Phase 1 |
| Completed | A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction NCT05478603 | Pfizer | Phase 1 |
| Terminated | A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mi NCT05376839 | AbbVie | Phase 1 |
| Completed | A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How NCT05419635 | Bayer | Phase 1 |
| Completed | A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) NCT05386589 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543 NCT05467722 | Concert Pharmaceuticals | Phase 1 |
| Completed | To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic I NCT05404529 | Cerevel Therapeutics, LLC | Phase 1 |
| Completed | Fruquintinib Hepatic Impairment Study NCT05216367 | Hutchmed | Phase 1 |
| Completed | Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment NCT04993157 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937) NCT05112952 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compa NCT05026996 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairm NCT05112419 | AstraZeneca | Phase 1 |
| Completed | Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe He NCT05078580 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function NCT05098054 | Takeda | Phase 1 |
| Recruiting | Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease NCT05045482 | Zydus Therapeutics Inc. | Phase 1 |
| Completed | An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and NCT04950764 | Gilead Sciences | Phase 1 |
| Completed | A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants Wit NCT04942964 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Unknown | A Single and Repeat Dose Trial in Participants With Hepatic Impairment NCT05009680 | Galecto Biotech AB | Phase 1 / Phase 2 |
| Completed | Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332 NCT05005312 | Pfizer | Phase 1 |
| Completed | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod NCT04819464 | Viatris Innovation GmbH | Phase 1 |
| Completed | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants NCT04960124 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment NCT04752540 | F2G Biotech GmbH | Phase 1 |
| Completed | Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairmen NCT04791553 | SK Life Science, Inc. | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment NCT04859426 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Completed | Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairm NCT04887064 | Amgen | Phase 1 |
| Completed | A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012) NCT04676425 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitrava NCT04772612 | Mirati Therapeutics Inc. | Phase 1 |
| Unknown | Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of NCT05101265 | PharmaMar | Phase 1 |
| Completed | Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function NCT04694365 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Surufatinib Hepatic Impairment Study NCT04755075 | Hutchison Medipharma Limited | Phase 1 |
| Unknown | An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Partici NCT04631549 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Withdrawn | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma NCT04759846 | Pierre Fabre Medicament | Phase 1 |
| Completed | STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT NCT04604496 | Pfizer | Phase 1 |
| Unknown | An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Partici NCT04631575 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Withdrawn | Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compa NCT03813979 | Radboud University Medical Center | Phase 4 |
| Completed | Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment NCT04573582 | Celgene | Phase 1 |
| Completed | To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Sev NCT04552808 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Sev NCT04056468 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK NCT04546789 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| Completed | A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment NCT04473664 | Daiichi Sankyo | Phase 1 |
| Unknown | A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy NCT04494269 | HK inno.N Corporation | Phase 1 |
| Completed | A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fe NCT04482270 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Terminated | A Study of JNJ-53718678 in Participants With Hepatic Impairment NCT04332523 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment NCT04305392 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics NCT04406896 | Viatris Innovation GmbH | Phase 1 |
| Completed | Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function NCT04469920 | Zydus Therapeutics Inc. | Phase 1 |
| Completed | The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics NCT04252495 | Idorsia Pharmaceuticals Ltd. | Phase 1 |
| Completed | A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Func NCT04332432 | Galectin Therapeutics Inc. | Phase 1 |
| Completed | Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment NCT04293029 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Recruiting | Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite NCT04271488 | Eisai Co., Ltd. | Phase 1 |
| Completed | Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment NCT04480827 | Galmed Research and Development, Ltd. | Phase 1 |
| Completed | A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT NCT04193436 | Pfizer | Phase 1 |
| Completed | A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants W NCT04225936 | Bristol-Myers Squibb | Phase 1 |
| Terminated | A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Modera NCT04241835 | Epizyme, Inc. | Phase 1 |
| Completed | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 NCT04208399 | Janssen Sciences Ireland UC | Phase 1 |
| Completed | A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989 NCT04208386 | Janssen Sciences Ireland UC | Phase 1 |
| Completed | A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant NCT06094725 | Corcept Therapeutics | Phase 1 |
| Completed | PVB Versus TAP in Hepatic Patients Undergoing Laparoscopic Cholecystectomy NCT04208165 | Theodor Bilharz Research Institute | N/A |
| Completed | KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impai NCT04166942 | Kadmon, a Sanofi Company | Phase 1 |
| Completed | Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite NCT04190654 | Kyowa Kirin, Inc. | Phase 1 |
| Completed | Study of Single-dose DS-3201b in Participants With Hepatic Impairment NCT04276662 | Daiichi Sankyo | Phase 1 |
| Completed | Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment NCT04145596 | Sichuan Haisco Pharmaceutical Group Co., Ltd | Phase 1 |
| Completed | A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal H NCT04154774 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With NCT04091061 | Pfizer | Phase 1 |
| Completed | A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairmen NCT03983161 | Celgene | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impa NCT04016077 | Pfizer | Phase 1 |
| Completed | A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function NCT03902002 | Biogen | Phase 1 |
| Completed | Study of Nalbuphine ER in Participants With Hepatic Impairment NCT04020016 | Trevi Therapeutics | Phase 1 |
| Completed | A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment NCT03816631 | Janssen-Cilag International NV | Phase 1 |
| Completed | Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function NCT03962049 | ObsEva SA | Phase 1 |
| Completed | Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared NCT03824678 | Celgene | Phase 1 |
| Completed | Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients NCT03765671 | Genfit | Phase 1 |
| Completed | A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants NCT05436912 | Eli Lilly and Company | Phase 1 |
| Completed | A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairm NCT03742882 | Celgene | Phase 1 |
| Terminated | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib NCT03587363 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabo NCT03968848 | Acerta Pharma BV | Phase 1 |
| Completed | Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects NCT03802786 | Poxel SA | Phase 1 |
| Completed | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib NCT03627754 | Pfizer | Phase 1 |
| Completed | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in NCT04643795 | Madrigal Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects NCT03722823 | Seagen Inc. | Phase 1 |
| Completed | A Hepatic Impairment Study for PF-04965842. NCT03626415 | Pfizer | Phase 1 |
| Completed | Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to NCT03706898 | Viriom | Phase 1 |
| Completed | Tepotinib Hepatic Impairment Trial NCT03546608 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Completed | A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function NCT03799848 | Akebia Therapeutics | Phase 1 |
| Withdrawn | A Study of LY3314814 in Participants With Liver Impairment NCT03499041 | Eli Lilly and Company | Phase 1 |
| Completed | Study of Danicopan in Participants With Hepatic Impairment NCT03555539 | Alexion Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Im NCT06004934 | Amgen | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Imp NCT03713242 | Idorsia Pharmaceuticals Ltd. | Phase 1 |
| Completed | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients NCT03359850 | Tesaro, Inc. | Phase 1 |
| Completed | Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Mo NCT03440424 | Eisai Inc. | Phase 1 |
| Completed | Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment NCT03309202 | Pfizer | Phase 1 |
| Unknown | The Role and Dynamics of Liver Dysfunction in Patients Undergoing Cardiac Surgery NCT02893657 | Semmelweis University Heart and Vascular Center | — |
| Completed | Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment NCT03423446 | Lexicon Pharmaceuticals | Phase 1 |
| Completed | Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impair NCT03369002 | Gilead Sciences | Phase 1 |
| Completed | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Anta NCT03397888 | Portola Pharmaceuticals | Phase 1 |
| Completed | A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous T NCT03277274 | Takeda | Phase 1 |
| Completed | A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function NCT03282513 | Agios Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic I NCT03290443 | Celgene | Phase 1 |
| Withdrawn | A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Com NCT03277755 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant NCT03212313 | Biotie Therapies Inc. | Phase 1 |
| Completed | Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites NCT03376841 | Allergan | Phase 1 |
| Completed | Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subje NCT03048448 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment an NCT03189615 | H. Lundbeck A/S | Phase 1 |
| Completed | Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment NCT03114540 | Pfizer | Phase 1 |
| Withdrawn | A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Hea NCT02985632 | Bristol-Myers Squibb | Phase 1 |
| Terminated | Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment NCT02873650 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment NCT03289234 | Tanabe Pharma Corporation | Phase 1 |
| Completed | A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects NCT02857868 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Ins NCT02683577 | Ipsen | Phase 1 |
| Completed | PK Study of T-817 in Subjects With Hepatic Impairment NCT02693197 | FUJIFILM Toyama Chemical Co., Ltd. | Phase 1 |
| Completed | Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment. NCT02624557 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib NCT02621047 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intra NCT02611505 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment NCT02581592 | Mylan Inc. | Phase 1 |
| Completed | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of AS NCT02571816 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairm NCT02524717 | Aragon Pharmaceuticals, Inc. | Phase 1 |
| Completed | INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function NCT02474537 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment NCT03160014 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | PK Study of Sotagliflozin in Subjects With Hepatic Impairment NCT02471274 | Lexicon Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal H NCT02452801 | Alkermes, Inc. | Phase 1 |
| Completed | A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function NCT02372084 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairm NCT02367872 | Takeda | Phase 1 |
| Completed | A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics NCT02286609 | PTC Therapeutics | Phase 1 |
| Completed | Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function NCT02296905 | AbbVie | Phase 1 |
| Completed | Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic NCT02115347 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment NCT02245243 | Melinta Therapeutics, Inc. | Phase 1 |
| Completed | Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment NCT02244827 | Wockhardt | Phase 1 |
| Completed | Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline NCT02256033 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Completed | Influence of Microfiltered-seawater Supplementation and Variable Resistance Training in Blood Pressure, Oxidat NCT06600243 | University of Valencia | N/A |
| Completed | Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment NCT02150733 | Daiichi Sankyo | Phase 1 |
| Completed | PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers NCT02121860 | Conatus Pharmaceuticals Inc. | Phase 1 |
| Terminated | MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function NCT02050815 | Array Biopharma, now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects NCT02095587 | SecuraBio | Phase 1 |
| Completed | A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic NCT03832426 | R-Pharm | Phase 1 |
| Completed | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Imp NCT01949545 | Amgen | Phase 1 |
| Completed | Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD Afte NCT02004587 | LG Life Sciences | Phase 1 |
| Completed | Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic F NCT01887301 | Jazz Pharmaceuticals | Phase 1 |
| Completed | Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Sub NCT01888393 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Completed | Hepatic Impairment Trial of Obeticholic Acid NCT01904539 | Intercept Pharmaceuticals | Phase 1 |
| Completed | EVP-6124 Hepatic Impairment Study NCT01984736 | FORUM Pharmaceuticals Inc | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment NCT01863784 | Janssen Research & Development, LLC | Phase 1 |
| Completed | An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hep NCT01790607 | Ono Pharma USA Inc | Phase 1 |
| Completed | An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency a NCT01767103 | ApoPharma | Phase 4 |
| Completed | Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment NCT01762462 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairme NCT01767948 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function NCT01732263 | Shire | Phase 1 |
| Completed | Pharmacokinetics of BAF312 in Patients With Hepatic Impairment NCT01565902 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects NCT01846455 | Indivior Inc. | Phase 4 |
| Completed | A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteer NCT01621633 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment NCT01600976 | Janssen Infectious Diseases BVBA | Phase 1 |
| Completed | A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function NCT01631097 | AVEO Pharmaceuticals, Inc. | Phase 1 |
| Completed | Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Sever NCT01563562 | Biogen | Phase 1 |
| Completed | Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment NCT01594957 | Novartis Pharmaceuticals | Phase 1 |
| Completed | The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries NCT04271098 | Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital | — |
| Completed | A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients NCT01516047 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function NCT01443481 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment NCT01727128 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects NCT01493869 | Exelixis | Phase 1 |
| Completed | A PK and Safety Study in Subjects With Hepatic Impairment NCT01431833 | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Completed | Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment NCT01419457 | MDVI, LLC | Phase 1 |
| Completed | Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy S NCT01433458 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepati NCT02421042 | Eisai Inc. | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Sub NCT01456663 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects Wi NCT01319279 | Cephalon | Phase 1 |
| Completed | PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Funct NCT01429337 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetics of AGO178 in Participants With Liver Impairment NCT01531309 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects NCT05391724 | Jazz Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic NCT02242734 | Zogenix, Inc. | Phase 1 |
| Completed | Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment NCT01271387 | Vanda Pharmaceuticals | Phase 1 |
| Completed | GSK1349572 Hepatic Impairment Study NCT01231529 | ViiV Healthcare | Phase 1 |
| Completed | A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function NCT01222455 | AstraZeneca | Phase 1 |
| Completed | Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy NCT01529294 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepat NCT01126086 | Sanofi | Phase 1 |
| Completed | Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment NCT01134185 | Movetis | Phase 1 |
| Completed | A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in H NCT01146938 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | BG9928 in Subjects With Hepatic Impairment NCT00858156 | Biogen | Phase 1 |
| Completed | A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics NCT01027169 | Newron Pharmaceuticals SPA | Phase 1 |
| Completed | Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects NCT00812305 | Pacira Pharmaceuticals, Inc | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment NCT00768209 | VIVUS LLC | Phase 1 |
| Completed | Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment NCT00828932 | Eisai Inc. | Phase 1 |
| Completed | TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately I NCT00736905 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Sev NCT00672581 | AstraZeneca | Phase 1 |
| Completed | Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours NCT00621725 | AstraZeneca | Phase 1 |
| Completed | A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function NCT00956306 | Dong-A Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared NCT00819468 | Shire | Phase 1 |
| Completed | Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox. NCT00432627 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Comparison Between Child-Pugh and Albumin-Bilirubin Scores NCT03534843 | Huazhong University of Science and Technology | — |
| Completed | Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment NCT00162097 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function NCT00791284 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 |